As investors buy from tech giants like Nvidia, many other compelling opportunities exist for those looking for growth. Driven by innovation, revenue growth, and an enviable market position, each of these 3 underappreciated stocks offers investors a unique opportunity for profitability. All of them have shown clear signs of potentially growing by double-digit growth in the next few months.These stocks have been overlooked in an environment of modest gains in anticipation of the upcoming economy. However, loo ...

Key TakeawaysRaymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform."The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women.Lenacapavir and PBC treatment seladelpar could see combined annual sales of $3.7 billion by 2030, according to Raymond James' model. Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “m ...

文章核心观点 - 生物科技公司吉利德科学公司(GILD)在HIV药物领域处于领先地位,但最近管线的挫折和收购相关费用的影响导致业绩受挫,股价承压 [1][2][3] - 公司的领先HIV业务保持良好势头,努力建立肿瘤业务以实现多元化也令人鼓舞,但晚期试验失败是一大打击,影响了投资者情绪 [4][5][6][10][11][12] - 公司通过收购和合作拓展管线,有利于业务多元化发展,但近期管线挫折仍是一大隐忧 [7][8] 根据目录分别总结 公司概况 - 吉利德科学公司是HIV药物领域的领导者,但近期管线挫折和收购费用影响了业绩和股价表现 [1][2][3] - 公司的HIV业务保持强劲增长,主导产品Biktarvy市占率达49%,预计2024年HIV药物销售将增长4% [4] - 公司通过收购和合作拓展管线,如收购CymaBay公司获得肝病候选药物,与Merus公司合作开发双靶点三元抗体 [7][8] 管线进展 - 公司的肿瘤业务包括CAR-T疗法和乳腺癌药物Trodelvy,Trodelvy表现强劲,有助于公司建立肿瘤业务 [10][11] - 但Trodelvy在尿路上皮癌和非小细胞肺癌适应症的晚期试验失败,对公司肿瘤业务拓展造成打击 [12] - 公司新药lenacapavir用于艾滋病预防的临床试验取得100%疗效,有望进一步巩固公司在HIV领域的地位 [5][6] 估值与财务 - 公司股价目前处于52周低位,2024年每股收益预测受收购费用影响有所下调 [13][15] - 公司估值指标如市销率等处于行业平均水平,长期每股收益预测呈上升趋势 [14][15] - 公司现金充裕,股息率4.6%,为长期投资者提供吸引力 [18]

文章核心观点 - 吉利德科学公司(GILD)股价在盘前交易中上涨2%,原因是雷蒙德詹姆斯券商将其评级从"市场执行"上调至"跑赢大盘" [1] - 券商认为,GILD未来5年将受益于两个关键药品候选物的支持,有望提高收入增长 [1] - 分析师对该股普遍持悲观态度,有14家券商给予"持有"评级,平均目标价为81.93美元,较上一交易日收盘价有22.9%的溢价空间 [2] - GILD今年在股市表现平平,年初至今下跌17.7%,但在5月底触及2022年10月以来的最低点后得到了62美元附近的支撑 [3] 行业分析 - 吉利德科学公司是一家制药公司,主要从事药品研发和销售 [1] - 公司目前有两个关键药品候选物,有望在未来5年内提高公司的收入增长 [1] - 分析师普遍对该公司持悲观态度,但也有券商看好其未来表现 [2] - 公司今年股价表现较弱,但在5月底触及低点后得到了一定支撑 [3]

Gilead Sciences, Foster City, CA Tomsmith585/iStock Unreleased via Getty ImagesGilead Sciences (NASDAQ:GILD) on Thursday announced positive topline results from an interim analysis of its Phase III PURPOSE 1 trial. The trial which tested the efficacy of twice-yearly lenacapavir versus once daily Truvada and Descovy in approximately 5,300 women at risk of contracting HIV in South Africa and Uganda, found 0 incident cases of HIV infection in the lenacapavir group. In other words, among the 2,124 treated wit ...

文章核心观点 - 吉利德科学公司(GILD)宣布其HIV预防药物lenacapavir在一项III期临床试验中取得100%的预防效果,即在2,134名参与者中没有发生任何HIV感染病例[4][5] - 这是有史以来第一个III期HIV预防试验取得零感染的结果,显示lenacapavir作为一种新的HIV预防工具具有很大潜力[8] - 公司将在2024年底或2025年初公布另一项针对男性和跨性别人群的关键试验(PURPOSE 2)的结果,如果结果同样积极,将有助于lenacapavir获批用于多个人群[11][12] 公司相关 - 吉利德是HIV治疗领域的主导企业,开发了首个单片治疗药物、首个预防药物以及首个长效注射治疗药物[13] - 公司目前已有两种获批的每日口服预防药物Truvada和Descovy,lenacapavir作为每半年注射一次的新型预防药物有望进一步巩固公司在HIV领域的地位[16] - 吉利德股价年初至今下跌15.4%,低于行业平均下跌7.8%[12] 行业相关 - 2021年FDA批准了GSK旗下的长效注射预防药物Apretude,这是另一种新型HIV预防选择[17][19] - GSK的HIV业务在第一季度实现了两位数增长,主要得益于其口服双药方案和长效注射药物的强劲需求[20] - 行业内其他公司如Ligand和ALX Oncology也有不错的表现,Ligand的2024和2025年每股收益预期均有所上调,ALX Oncology的亏损预期也有所收窄[21][22][23]

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections. Given the stock's underperformance this year, this news is a significant relief for investors. Let's delve into the trial's details, the stock's recent performance, and its future prospects.Get Gilead Sciences alerts:Gilead's Lenacapa ...

Gilead Sciences (GILD) shares soared 8.5% in the last trading session to close at $68.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.The surge is mostly attributable to positive results from the late study PURPOSE 1 wherein twice-yearly lenacapavir demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy.  On the basis of these results, ...

Key TakeawaysA Phase 3 trial of Gilead's injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women. Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants.More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval.Shares of Gilead surged Thursday following the news. Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...